India approves AstraZeneca's Covid-19 vaccine for emergency use

It is the first Covid-19 vaccine to be approved for emergency use by India, which has the highest number of infections after the United States

AstraZeneca
AstraZeneca Covid-19 vaccine. File Photo: Reuters
Reuters
1 min read Last Updated : Jan 02 2021 | 4:18 PM IST
India has approved the COVID-19 vaccine developed by AstraZeneca and Oxford University, paving the way for a huge immunisation campaign in the world’s second most populous country.

Information and Broadcasting Minister Prakash Javadekar told reporters on Saturday the vaccine had been approved on Friday, confirming what sources close to the matter had told Reuters.

It is the first COVID-19 vaccine to be approved for emergency use by India, which has the highest number of infections after the United States.

Javadekar said at least three more vaccines were waiting in line to be approved.

“India is perhaps the only country where at least four vaccines are getting ready,” he said.

“One was approved yesterday for emergency use, Serum’s COVISHIELD.” he said, referring to the fact that the shot is being made locally by the Serum Institute of India (SII).

India has reported more than 10 million COVID-19 cases, though its rate of infection has come down significantly from a mid-September peak.

The country hopes to inoculate 300 million of its 1.35 billion people in the first six to eight months of 2021.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineAstraZeneca

Next Story